Traders should monitor patient volume disclosures and any future revenue guidance from Optimi, as this regulatory expansion is a positive catalyst but lacks concrete financial quantification. Near-term price action may reflect sentiment on the expanded addressable market rather than booked revenue.
Price Chart
Executive Summary
Optimi Health Corp. acknowledged final TGA recommendations expanding the Authorized Prescriber scheme for psilocybin and MDMA in Australia. The updated framework broadens therapist eligibility, allows treatment outside hospital settings, and expands reimbursement to public and private payers, which could increase patient volumes for Optimi's GMP-grade drug products. However, the filing contains no financial figures, revenue data, or concrete volume commitments.
Key Facts
- TGA updated framework broadens therapist eligibility to include psychotherapists, counsellors, social workers, and Indigenous health workers.
- Treatment can now occur in any medically supervised environment meeting safety standards, not limited to hospital settings.
- No serious adverse events reported under the AP scheme since December 2025.
- Reimbursement now includes public payers (DVA, NDIS, WorkCover) and private insurer Medibank.
- More than 750 clinicians trained via the CPAT program by Mind Medicine Australia.
- Optimi supplies GMP-grade MDMA and psilocybin from Canada to Australian patients under the scheme.
Financial Impact
No financial figures, revenue, or volume data provided in the filing. The regulatory expansion is a qualitative tailwind for potential commercial demand.
Risk Factors
- No specific financial data, revenue, or volume commitments disclosed in the filing.
- Psychedelic therapy reimbursement and adoption remain nascent and subject to regulatory and political risk.
- Company is pre-revenue or early-stage commercial — stock may be volatile on news flow rather than fundamentals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-247169 |
| Document: d102564d6k.htm | 0001193125-26-247169 |
| Document: 0001193125-26-247169-index-headers.html | 0001193125-26-247169 |
| Document: 0001193125-26-247169-index.html | 0001193125-26-247169 |
| Document: 0001193125-26-247169.txt | 0001193125-26-247169 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.36 | awaiting T+5 | — | $3.12 (−7.14%) |
Oct 20, 2026 6d ago | 6-K | $3.36 | awaiting T+5 | — | $3.12 (−7.14%) |
Oct 7, 2026 19d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.12 (−22.77%) |
Oct 5, 2026 21d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.12 (−24.46%) |
Sep 29, 2026 27d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.12 (−34.73%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.12 (−37.10%) |
Sep 22, 2026 4w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.12 (−37.10%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.12 (−36.33%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.12 (−30.67%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.12 (+36.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers